Asad Bashey, M.D., Ph. D.

Asad Bashey, M.D., Ph. D. is board certified in the subspecialties of medical oncology and hematology. He is the clinical research Medical Director for The Blood and Marrow Transplant Program at Northside Hospital. Dr. Bashey is also a Northside Hospital Leukemia Program physician. From 2013 – 2022, Dr. Bashey was recognized as among Atlanta’s Top Doctors in his specialty by Castle Connolly.


  • University of Dundee in Scotland, where he graduated with Commendation
  • Residency training, University of Edinburgh, Scotland
  • Fellowship training in bone marrow transplantation and leukemia therapy at the Hammersmith Hospital (Royal Postgraduate Medical School, now Imperial College School of Medicine) in London, UK.
  • Awarded Ph.D. from the University of London for his research related to leukemia
  • Completed further specialty training/BMT at University California, San Diego’s (UCSD) Moores Cancer Center in La Jolla, California

Society Memberships

  • American Society of Clinical Oncology
  • American Society of Hematology
  • American Society of Blood and Marrow Transplantation

Past Academic Faculty Appointments

  • UCSD Moores Cancer Center -Associate Professor: Clinical Director of the Bone Marrow Transplant Program and the Clinical Services Chief for the BMT Division.


  • Authored and co-authored more than 220 research articles and abstracts in peer-reviewed journals; New England Journal of Medicine, Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation
  • Primary author of several books including “Non-Myeloblative Allogeneic Transplantation” (2002) and “100 Questions and Answers on Myeloma” (2nd edition 2009), and Haplo Transplant Versus Cord Blood Transplant, Hematopoietic Transplantation: Bone Marrow, Blood and Cell Therapies.  Cambridge University Press, Cambridge, United Kingdom. 2014- In press.

Dr. Bashey’s clinical and research interests include novel approaches to allogeneic bone marrow transplantation, strategies for augmentation of the graft-versus-tumor effect after allogeneic transplantation, and stem cell mobilization. He has received major clinical research funding from the National Institutes of Health.